Using hydrogen peroxide to control bleeding during cesarean delivery for placenta previa and accreta
Efficacy of Hydrogen Peroxide ( H2O2) in Controlling Placental Site Bleeding in Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)
This study is testing if using hydrogen peroxide can help control bleeding during cesarean deliveries for pregnant women with placenta previa and accreta.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06030492 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of hydrogen peroxide in managing bleeding during cesarean sections for patients diagnosed with placenta previa and accreta spectrum. A total of 84 pregnant women will be randomly assigned to receive either hydrogen peroxide or normal saline at the placental site to assess its impact on controlling hemorrhage. The study aims to determine if hydrogen peroxide can reduce operative time and improve outcomes for these high-risk patients. The trial is conducted at Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women aged 18-40 with a BMI under 35, diagnosed with placenta previa and FIGO grade 1 placenta accreta.
Not a fit: Patients who are vitally unstable, have massive bleeding, or have higher grades of placenta accreta (FIGO grades 2 or 3) may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce maternal morbidity and mortality associated with severe bleeding during cesarean deliveries for placenta previa and accreta.
How similar studies have performed: While the use of hydrogen peroxide for hemostasis has shown promise in other surgical contexts, this specific application in placenta previa and accreta is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 18-40 years * BMI \< 35 kg/m2 * Pregnant patients with placenta previa . * Placenta accrete FIGO grade 1 . * Vitally stable . * Candidate for conservative management. * No major intra-operative bleeding. Exclusion Criteria: * Vitally unstable . * Massive pre- or intra-operative bleeding. * Medical disorders ( e.g. : hypertension , cardiac .... ) * Placenta accrete , FIGO grades 2 or 3 . * Not indicated for conservative management.
Where this trial is running
Cairo
- Kasr Alainy outpatient infertility clinic — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: bassiony dabian, MD
- Email: bassiony.dabian@gmail.com
- Phone: 1095195513
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.